India is all set to get its first coronavirus vaccine.The name of the medicine is Covishield — the Oxford University-Astra-Zeneca vaccine candidate will be commercialised and available in the market in 73 days.
An official at the Serum Institute of India said on Saturday resolved the mystery.
The India Today news reported that the Phase III trials of the vaccine have been handled by the Serum Institute of India. The vaccine which was developed by Oxford University is most probably be the first vaccine into production in India.
A Business Today report quoted a Serum Institute of India (SII) top official saying that the government has given the biotechnology company “a ‘special manufacturing priority license’ and fast-tracked the trial protocol processes to get the trials completed in 58 days.”
A Top Official said, “By this, the first dosing will take place today [Saturday] in the final phase [Phase III] and the second dosing will happen after 29 days. The final trial report will be out in another 15 days from the second dosing. By that time, we are planning to commercialise Covishield.”
On August 27, the phase III trials of the vaccine began on Saturday at 20 centres in India most importantly in Pune and Mumbai in Maharashtra and Ahmedabad in Gujarat. The vaccine will be administered to 1,600 people as for this phase.
The news of Oxford University-AstraZeneca vaccine that it has entered the trial phase have initiated a positive news.
Business Today report said that the vaccine will be of the Serum Institute officially. It said the company has entered into an “exclusive agreement with Astra Zeneca to buy rights and pay a royalty fee for exclusively selling it in India and 92 other countries”as quoted.
The Centre has already indicated to SII that it will directly transfer the vaccines and is planning to immunise Indians for free as per reports.
The government has also took 68 crore doses for 130 crore Indian citizens from the Serum Institute by June next year.
Several reports mentioned that around 800 people would be administered the Oxford University’s vaccine reportedly.They said the authorised developers have already signed a deal for producing 10 crore doses of the vaccine.
The ICMR-Bharat Biotech’s ‘Covaxine’ and Zydus Cadila’s ‘ZyCoV-D’ are also in the race. The vaccine candidates has developed by Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR), and Zydus Cadila, are in human clinical trials in phase-I and II simultaneously.